Victoria Villaflor

City Of Hope National Medical Center — United States

Medicine · Health Sciences

33h-index4.8kcitations242works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(76), Cancer Immunotherapy and Biomarkers(43), Head and Neck Cancer Studies(43), Lung Cancer Research Studies(39), Cancer Genomics and Diagnostics(29)

Publications242 total

Supplementary figures S1-S5 from Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in <i>PIK3CA</i>- and <i>HRAS</i>-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
2025Open Access
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer
UNC Libraries·2025Open Access
1366P Evaluating HPV DNA clearance on survival outcomes in HPV+ oropharyngeal carcinoma
Annals of Oncology·2025
Evaluating Clinical Factors Including HPV Clearance on Survival Outcomes in HPV+ Oropharyngeal Carcinoma
Cancers·2025Open Access
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Journal for ImmunoTherapy of Cancer·2025· 3 citedOpen Access
Abstract CT206: ICAM-1 directed chimeric antigen receptor (CAR) T cells (AIC100) in patients with advanced thyroid cancers: Clinical and translational data from the phase 1 dose escalation study
Cancer Research·2025
Phase <scp>II</scp> Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (<scp>ACC</scp>) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors
Cancer Medicine·2025· 3 citedOpen Access
Abstract B045: The impact of smoking status on the genomic landscape of lung squamous cell carcinoma
Clinical Cancer Research·2024
Supplementary figures S1-S5 from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
2024Open Access
Supplementary figures S1-S5 from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
2024Open Access
Supplementary figures S1-S5 from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
2024Open Access
Data from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
2024Open Access
Data from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
2024Open Access
Supplementary figures S1-S5 from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
2024Open Access
Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors
Cancer Immunology Immunotherapy·2024· 7 citedOpen Access
Barriers to and enablers of physical activity participation in lung cancer survivors
PM&R·2024· 5 citedOpen Access
Safety and efficacy of AIC100 chimeric antigen receptor (CAR) T-cell therapy in patients with advanced thyroid cancers: Results from the phase 1 study.
Journal of Clinical Oncology·2024· 8 cited
A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck.
Journal of Clinical Oncology·2024
Phase II study of nivolumab and ipilimumab for treatment of metastatic/recurrent adenoid cystic carcinoma (ACC) of all anatomic sites of origin and other malignant salivary gland tumors
2024· 1 citedOpen Access
Abstract CT191: First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data
Cancer Research·2024
page 1 of 13Next →

Frequent Co-authors

Everett E. Vokes(18), Tanguy Y. Seiwert(14), Ezra E.W. Cohen(13), Daniel J. Haraf(12), Ravi Salgia(11), Elizabeth A. Blair(10), Joseph K. Salama(9), Young Kwang Chae(8), Nisha Mohindra(7), Francis J. Giles(6), Mark W. Lingen(6), Kerstin Stenson(6), Theodore Karrison(5), Masha Kocherginsky(5), Daniel Thomas Ginat(5), Philip C. Hoffman(4), J.M. Melotek(4), Ryan J. Brisson(4), A. Dekker(4), Erminia Massarelli(4)